Monoclonal Antibodies

dc.contributor.author	Christian Klein (Ed.)	*
dc.date.accessioned	2021-02-11T20:08:20Z
dc.date.available	2021-02-11T20:08:20Z
dc.date.issued	2018	*
dc.date.submitted	2018-04-27 13:43:10	*
dc.identifier	26622	*
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/53915
dc.description.abstract	Monoclonal antibodies are established in clinical practice for the treatment of cancer, and autoimmune and infectious diseases. The first generation of antibodies has been dominated by classical IgG antibodies, however, in the last decade, the field has advanced, and, nowadays, a large proportion of antibodies in development have been engineered. This Special Issue on "Monoclonal Antibodies" includes original manuscripts and reviews covering various aspects related to the discovery, analytical characterization, manufacturing and development of therapeutic and engineered antibodies.	*
dc.language	English	*
dc.subject	R5-920	*
dc.subject	RC581-607	*
dc.subject.classification	thema EDItEUR::M Medicine and Nursing	en_US
dc.subject.other	antibody drug conjugates	*
dc.subject.other	bispecific antibodies	*
dc.subject.other	engineered antibodies	*
dc.subject.other	antibody-like scaffolds	*
dc.subject.other	monoclonal antibodies	*
dc.title	Monoclonal Antibodies	*
dc.type	book
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0	*
oapen.relation.isbn	9783038428763	*
oapen.relation.isbn	9783038428756	*
oapen.pages	X, 228	*
oapen.edition	1st	*

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/